4 results
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
The present study protocol proposes a novel cGMP Enhancing Therapeutic Strategy (cGETS) to 1) enhance plasma levels of cGMP, 2) to increase cGMP-related control of the myocardial response to low dose dobutamine stress testing, 3) to improveā¦
To evaluate the efficacy and safety of STS compared to placebo treatment on myocardial infarct size in patients presenting with STEMI and treated with PCI and in adjunction to optimal reperfusion therapy.
to evaluate the safety and maximum tolerable dose of sodium thiosulfate in patients presenting with acute coronary syndrome undergoing coronary angiography via transradial approach, when given in combination with concomitant vasodilator drugs.